Doximity has acquired Montreal-based Pathway Medical and will integrate the startup´s clinician-facing large language model into its products, the company said. The San Francisco-based software firm completed the acquisition late last month. Terms included an upfront cash payment and the possibility of additional equity consideration, according to the report; the outlet that first described the terms said a cash payment was made with potential equity to follow.
Founded in 2020, Pathway developed a chatbot doctors could query about treatment options and drug dosages. That tool relied on a proprietary large language model trained on papers from medical journals, a narrow, domain-specific approach aimed at clinical reference rather than general conversation. Pre-acquisition fundraising included venture backing from Desjardins Capital, Panache Ventures and founders of canadian medtech firms Figure1 and Dialogue, based on PitchBook data cited in the story. The startup´s team was small: all six Pathway employees will join Doximity as part of the transaction.
Doximity makes an app clinicians use for virtual appointments and professional networking. Executives said they plan to build Pathway´s model into that stack to enhance clinical workflows and reference capabilities for physicians. The company, through spokesperson Amanda Cox, said it does not currently plan to expand operations in Montreal despite hiring the six staff. That decision suggests the acquisition is primarily for technology and talent that can be folded into Doximity´s existing product roadmap rather than an opening of a new regional office.
The deal underlines a continued trend of established health-tech platforms buying specialist startups to accelerate machine learning and clinical features. Regulators and users will watch how Doximity validates and governs the integrated model, particularly for dosing and treatment advice where accuracy and provenance matter. Murad Hemmadi reported the acquisition for The Logic on Aug 8, 2025; the company has framed the move as product enhancement and team absorption rather than geographic expansion.
